|
Back to products
Browse products
Approved anticancer agents
Anticancer agents in trials
Anticancer molecular libraries
Other drug agents
Drug intermediates
Bio-reagents and biochemicals
|
MedKoo product information:
CF-101
|
MedKoo Code#:
200740
|
|
Name:
CF-101
|
|
CAS#:
152918-18-8
Synonym: CF-101;
IB-MECA; N6-(3-Iodobenzyl)adenosine-5'-N-methyluronamide;
-D-Ribofuranuronamide,
1-deoxy-1-[6-[[(3-iodophenyl)methyl]amino]-9H-purin-9-yl]-N-methyl-.
IUPAC/Chemical name:
(2S,3S,4R,5R)-3,4-dihydroxy-5-(6-(3-iodobenzylamino)-9H-purin-9-yl)-N-methyltetrahydrofuran-2-carboxamide。
|
|
Chemical structure
|
Theoretical analysis
|
|
|
Chemical Formula: C18H19IN6O4
Exact Mass: 510.05125
Molecular Weight: 510.28
m/z: 510.05125 (100.0%), 511.05460 (19.5%),
511.04828 (2.2%), 512.05796 (1.8%)
Elemental Analysis: C, 42.37; H, 3.75; I,
24.87; N, 16.47; O, 12.54
|
|
Availability and price:
This agent is not in stock, which may be available through custom synthesis. To inquire quotation and lead time or to ask questions, please send email to
sales@medkoo.com to describe your needs. A representative
will respond your email shortly. We offer big discount for orders of bulk quantities.
|
|
Quality control
data:
Product will be shipped with
supporting analytical data.
|
|
Information about this agent
|
CF101, a specific agonist to the A3
adenosine receptor, inhibits the development of colon carcinoma growth
in cell cultures and xenograft murine models. CF101 has been shown to
downregulate PKB/Akt and NF-κB protein expression level. CF101
potentiates the cytotoxic effect of 5-FU, thus preventing drug
resistance. The myeloprotective effect of CF101 suggests its development
as an add-on treatment to 5-FU.
Current developer: Can-Fite
BioPharma
1: Avni I, Garzozi HJ, Barequet IS, Segev F,
Varssano D, Sartani G, Chetrit N, Bakshi E, Zadok D, Tomkins O, Litvin
G, Jacobson KA, Fishman S, Harpaz Z, Farbstein M, Yehuda SB, Silverman
MH, Kerns WD, Bristol DR, Cohn I, Fishman P. Treatment of Dry Eye
Syndrome with Orally Administered CF101 Data from a Phase 2 Clinical
Trial. Ophthalmology. 2010 Mar 19. [Epub ahead of print] PubMed PMID:
20304499.
2: Bar-Yehuda S, Rath-Wolfson L, Del Valle L, Ochaion A, Cohen S, Patoka
R, Zozulya G, Barer F, Atar E, Piña-Oviedo S, Perez-Liz G, Castel D,
Fishman P. Induction of an antiinflammatory effect and prevention of
cartilage damage in rat knee osteoarthritis by CF101 treatment.
Arthritis Rheum. 2009 Oct;60(10):3061-71. PubMed PMID: 19790055.
3: Borea PA, Gessi S, Bar-Yehuda S, Fishman P. A3 adenosine receptor:
pharmacology and role in disease. Handb Exp Pharmacol.
2009;(193):297-327. Review. PubMed PMID: 19639286.
4: Moral MA, Tomillero A. Gateways to clinical trials. Methods Find Exp
Clin Pharmacol. 2008 Mar;30(2):149-71. PubMed PMID: 18560631.
5: Silverman MH, Strand V, Markovits D, Nahir M, Reitblat T, Molad Y,
Rosner I, Rozenbaum M, Mader R, Adawi M, Caspi D, Tishler M, Langevitz
P, Rubinow A, Friedman J, Green L, Tanay A, Ochaion A, Cohen S, Kerns
WD, Cohn I, Fishman-Furman S, Farbstein M, Yehuda SB, Fishman P.
Clinical evidence for utilization of the A3 adenosine receptor as a
target to treat rheumatoid arthritis: data from a phase II clinical
trial. J Rheumatol. 2008 Jan;35(1):41-8. Epub 2007 Nov 15. PubMed PMID:
18050382.
6: Bar-Yehuda S, Silverman MH, Kerns WD, Ochaion A, Cohen S, Fishman P.
The anti-inflammatory effect of A3 adenosine receptor agonists: a novel
targeted therapy for rheumatoid arthritis. Expert Opin Investig Drugs.
2007 Oct;16(10):1601-13. Review. PubMed PMID: 17922624.
7: Ochaion A, Bar-Yehuda S, Cohn S, Del Valle L, Perez-Liz G, Madi L,
Barer F, Farbstein M, Fishman-Furman S, Reitblat T, Reitblat A, Amital
H, Levi Y, Molad Y, Mader R, Tishler M, Langevitz P, Zabutti A, Fishman
P. Methotrexate enhances the anti-inflammatory effect of CF101 via
up-regulation of the A3 adenosine receptor expression. Arthritis Res
Ther. 2006;8(6):R169. PubMed PMID: 17101059; PubMed Central PMCID:
PMC1794513.
8: Xu W, Zheng S, Goggans TM, Kiser P, Quinones-Mateu ME, Janocha AJ,
Comhair SA, Slee R, Williams BR, Erzurum SC. Cystic fibrosis and normal
human airway epithelial cell response to influenza a viral infection. J
Interferon Cytokine Res. 2006 Sep;26(9):609-27. PubMed PMID: 16978065.
9: Baharav E, Bar-Yehuda S, Madi L, Silberman D, Rath-Wolfson L, Halpren
M, Ochaion A, Weinberger A, Fishman P. Antiinflammatory effect of A3
adenosine receptor agonists in murine autoimmune arthritis models. J
Rheumatol. 2005 Mar;32(3):469-76. PubMed PMID: 15742438.
10: Bar-Yehuda S, Madi L, Silberman D, Gery S, Shkapenuk M, Fishman P.
CF101, an agonist to the A3 adenosine receptor, enhances the
chemotherapeutic effect of 5-fluorouracil in a colon carcinoma murine
model. Neoplasia. 2005 Jan;7(1):85-90. PubMed PMID: 15720820; PubMed
Central PMCID: PMC1490317.
11: van Troostenburg AR, Clark EV, Carey WD, Warrington SJ, Kerns WD,
Cohn I, Silverman MH, Bar-Yehuda S, Fong KL, Fishman P. Tolerability,
pharmacokinetics and concentration-dependent hemodynamic effects of oral
CF101, an A3 adenosine receptor agonist, in healthy young men. Int J
Clin Pharmacol Ther. 2004 Oct;42(10):534-42. PubMed PMID: 15516022.
12: O'Sullivan LA, Fuller KE, Thomas EM, Turley CM, Fry JC, Weightman
AJ. Distribution and culturability of the uncultivated 'AGG58 cluster'
of the Bacteroidetes phylum in aquatic environments. FEMS Microbiol
Ecol. 2004 Mar 1;47(3):359-70. PubMed PMID: 19712324.
13: Fishman P, Bar-Yehuda S, Ohana G, Barer F, Ochaion A, Erlanger A,
Madi L. An agonist to the A3 adenosine receptor inhibits colon carcinoma
growth in mice via modulation of GSK-3 beta and NF-kappa B. Oncogene.
2004 Apr 1;23(14):2465-71. PubMed PMID: 14691449.
14: Ohana G, Bar-Yehuda S, Arich A, Madi L, Dreznick Z, Rath-Wolfson L,
Silberman D, Slosman G, Fishman P. Inhibition of primary colon carcinoma
growth and liver metastasis by the A3 adenosine receptor agonist CF101.
Br J Cancer. 2003 Oct 20;89(8):1552-8. PubMed PMID: 14562031; PubMed
Central PMCID: PMC2394357.
15: Bar-Yehuda S, Madi L, Barak D, Mittelman M, Ardon E, Ochaion A, Cohn
S, Fishman P. Agonists to the A3 adenosine receptor induce G-CSF
production via NF-kappaB activation: a new class of myeloprotective
agents. Exp Hematol. 2002 Dec;30(12):1390-8. PubMed PMID: 12482500.
16: Khurana AK, Saraya A, Jain N, Chandra M, Kulshreshta R. Profile of
lower gastrointestinal bleeding in children from a tropical country.
Trop Gastroenterol. 1998 Apr-Jun;19(2):70-1. PubMed PMID: 9752757.
17: Moyle WR, Campbell RK, Myers RV, Bernard MP, Han Y, Wang X.
Co-evolution of ligand-receptor pairs. Nature. 1994 Mar
17;368(6468):251-5. PubMed PMID: 8145825.
|
Contact MedKoo:
Email:
sales@medkoo.com
(Keyword; CAS#; MedKoo code#)
|
